Cyclo Therapeutics (NASDAQ:CYTH) versus SOPHiA GENETICS (NASDAQ:SOPH) Financial Contrast

Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Insider & Institutional Ownership

68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Cyclo Therapeutics and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.

Cyclo Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Cyclo Therapeutics and SOPHiA GENETICS, as reported by MarketBeat.

Cyclo Therapeutics presently has a consensus price target of $0.95, suggesting a potential upside of 31.94%. SOPHiA GENETICS has a consensus price target of $6.50, suggesting a potential upside of 74.26%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Cyclo Therapeutics.

Risk and Volatility

Cyclo Therapeutics has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.

Profitability

This table compares Cyclo Therapeutics and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Summary

SOPHiA GENETICS beats Cyclo Therapeutics on 8 of the 14 factors compared between the two stocks.

About Cyclo Therapeutics

(Get Free Report)

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.